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httcense.Abstract Objective: The purpose of the current study was to determine the usefulness of the usage
of the spleen as a reference organ to normalize liver ADC to improve the diagnostic performance of
diffusion weighted imaging (DWI) for assessing liver ﬁbrosis.
Materials and methods: Forty-nine subjects, 34 patients with liver disease and 15 control subjects
were assessed with diffusion-weighted imaging. Liver ADC and normalized liver ADC (deﬁned as
the ratio of liver ADC to spleen ADC) were compared between patients and the control groups as
well as among patients with different stages of ﬁbrosis. Receiver operating characteristic (ROC)
analysis was used to determine the performance of ADC and normalized liver ADC for prediction
of liver ﬁbrosis and cirrhosis.
Results: There was no signiﬁcant difference between spleen ADC values among patients in com-
parison to control (1.107 ± 0.07 · 103mm2/s vs. 1.12 ± 0.068 · 103mm2/s, p= 0.998) or among
patients with different stages of ﬁbrosis (p= 0.59–0.89). The mean liver ADC and mean normalized
liver ADC values were signiﬁcantly lower in patients with hepatic ﬁbrosis compared to volunteers
(P= 0.01,<0.001 respectively), however liver ADC could not signiﬁcantly differentiate different
stages of ﬁbrosis except between stages 0 and 4. The mean normalized liver ADC was signiﬁcantly
different between stage 0 and stages 2, 3, and 4 as well as between stage 1 and stage 4. In addition, it
had a trend toward signiﬁcance between stage 0 and 1, stage 2 and 4 as well as stage 3 and 4. Both
liver ADC and normalized liver ADC had a signiﬁcant negative correlation with the grade of ﬁbro-
sis, however it was more powerful for normalized liver ADC in comparison to liver ADC
(r= 0.694 vs. 0.361, p= 0.01 vs. 0.05). ROC analysis showed higher performance using0089059.
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442 M. El-Hariri et al.normalized liver ADC in comparison to liver ADC, with higher AUC, sensitivity, and speciﬁcity for
detection of ﬁbrotic stages P2 (0.88, 92.5% and 76.2% Vs 0.72, 82.1%, and 57.1% respectively).
The corresponding values for stages P3 were 0.83, 100%, and 55% vs. 0.69, 77.3%, and 44.4%
respectively), while the corresponding values for cirrhosis (stage 4) were 0.87, 81.8%, and 81.8%
for normalized liver ADC vs. 0.74, 69.2%, 72.2%.for ADC liver.
Conclusion: The utility of using the spleen as a reference organ could improve the diagnostic per-
formance of ADC measurement for the diagnosis of liver ﬁbrosis. The application of this technique
for the evaluation of liver ﬁbrosis is promising.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND  license.1. Introduction
Liver ﬁbrosis is a consequence of sustained prolonged injury
from a variety of causes, including viral, autoimmune, chole-
static, alcohol-and drug-induced, and metabolic diseases. The
progression of ﬁbrosis ultimately leads to the hepatic architec-
tural distortion and may result in cirrhosis, hepatic failure and
portal hypertension (1–9).
Early ﬁbrosis progression can be reversed by treatment with
speciﬁc antiﬁbrotic therapy or by removal of the cause if pos-
sible, therefore, identiﬁcation of the early liver ﬁbrosis is cru-
cial (1,2,8,9). Liver histology is frequently considered the
gold standard for assessing hepatic ﬁbrosis, however, liver
biopsy is relatively invasive and limited by sampling errors, in-
tra- and inter-observer variation and difﬁculty to repeat. In
addition pain and major complications occurred in 40% and
0.5% of patients respectively. Therefore, reliable and non-
invasive tools for diagnosis and quantiﬁcation of hepatic ﬁbro-
sis are essentially required (1,3,10–16).
Diffusion weighted MRI (DW-MRI) is a technique that
interrogates and quantiﬁes motion of water molecules in tis-
sues and hence derives image contrast based on differences
in the mobility of protons (primarily associated with water)
in tissues. Water diffusion is quantiﬁed by calculation of the
apparent diffusion coefﬁcient (ADC) (13,17).
DW-MRI has many advantages, for example it is quick
(could be performed within a breath-hold) and performed
without the use of contrast media), with recent advances in
technology, DW-MRI is increasingly applied in the abdomen
with promising results. Application of DW-MRI in the diag-
nosis of liver ﬁbrosis is achieving promising results (13,17–20).
Highly cellular tissues and the higher density of cell mem-
branes restrict the apparent diffusion of water protons, while,
higher water molecule movement occurs in cystic or necrotic
tissues. Liver ﬁbrosis leads to extracellular accumulation of
collagen, glycosaminoglycans, and proteoglycans with subse-
quent restriction of the molecular diffusion of water
(1,13,17,23).
In order to reducing the variability in ADC calculations,
the normalization of ADC using a relatively constant reference
organ can be applied. The incomplete visualization of kidneys
in single-shot echo-planar imaging (EPI) images owing to re-
duced size of cirrhotic liver interferes with its usage as a refer-
ence organ. The variability in size and intramuscular and as
well as overlapping ghosting artifact with single-shot EPI se-
quence are all making the paraspinal muscles not ideal as a ref-
erence organ. The spleen may be an ideal reference organ, as it
has a relatively stable ADC even in the setting of liver disease.In addition, its position relative to the diaphragm is similar to
the liver (21,24–26).
The purpose of the current study was to determine the use-
fulness of the usage of the spleen as a reference organ to nor-
malize liver ADC to improve the diagnostic performance of
DWI for assessing liver ﬁbrosis.
2. Material and methods
2.1. Patients and control subjects
This study was approved by our institutional review board.
Written informed consent was obtained from all participants.
We had a total of 40 consecutive patients who were previ-
ously diagnosed as chronic viral hepatitis on the basis of clin-
ical history supported by laboratory tests and ongoing
percutaneous liver biopsy. Of these 40 patients, 34 patients
were included in this study (case group), while 6 patients were
excluded because of contraindication to liver biopsy (n= 3),
absolute MR contraindication (n= 1) while 2 patients refused
MR examination.
Fifteen control subjects with matched age were included, so
ﬁnally we had 49 subjects (32 males, 17 females) with a mean
age of 46 years (rang (32–58 years).
2.1.1. Case group
Thirty-four patients (23 males, 11 females) who were previ-
ously diagnosed as chronic viral hepatitis on the basis of clin-
ical history supported by laboratory tests and ongoing
percutaneous liver biopsy. Mean age 47.5 years (range 32–
58 years),
2.1.2. Control group
Fifteen control volunteers with matched age (9 men and 6 wo-
men; mean age 46.5 years; range 33–57 years) with no MRI
imaging absolute contraindication, normal liver function tests,
no history of hepatitis or diffuse liver disease and normal liver
imaging ﬁndings apart from hepatic haemangioma and/or
small liver cyst.
2.1.3. MRI protocol
All examinations were performed using 1.5 Tesla MR scanner
(Philips Medical Systems, Achieva). DWI was performed with
a phased array superﬁcial body coil in a single acquisition
using a single-shot echo-planar imaging (EPI) sequence during
a single end expiratory breath-hold. The following parameter
was used: scan time: 6 min, TR/TE: 1300–3400, 67–82 m/s,
slice thickness: 8 mm, interslice gap: 1.6 mm, ﬁeld of view:
Table 1 The mean liver ADC (±SD), normalized liver ADC and spleen ADC values of the liver in different grades of hepatic ﬁbrosis
according to METAVIR score.
Stage of ﬁbrosis No. Liver ADC (103 mm2/s) Normalized liver ADC Spleen ADC (103 mm2/s)
F0 15 1.67 ± 0.169 1.51 ± 0.022 1.12 ± 0.069
F1 6 1.64 ± 0.017 1.48 ± 0.049 1.04 ± 0.041
F2 6 1.58 ± 0.012 1.46 ± 0.038 1.09 ± 0.046
F3 9 1.60 ± 0.13 1.46 ± 0.013 1.14 ± 0 .076
F4 13 1.56 ± 0.016 1.44 ± 0.02 1.12 ± 0.074
Fig. 1 DWI at b= 0 (a), b= 500(b), and ADC map(c) for a volunteer (stage 0 ﬁbrosis): liver ADC= 1.68 · 103 mm2/s and
normalized liver ADC= 1.52.
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Table 2 ADC comparison among different ﬁbrosis stages.
Fibrosis stage Liver ADC
(P-value)
Normalized liver
ADC (P-value)
F0 vs. F1 0.55 0.08
F0 vs. F2 0.10 0.003
F0 vs. F3 0.17 0.001
F0 vs. F4 0.01 <0.001
F1 vs. F2 0.37 0.25
F1 vs. F3 0.57 0.19
F1 vs. F4 0.17 <0.001
F2 vs. F3 0.68 0.97
F2 vs. F4 0.73 0.07
F3 vs. F4 0.38 0.06
F0–1 vs. F2–4 0.01 <0.001
F0–2 vs. F3–4 0.04 <0.001
F0–3 vs. F4 0.003 <0.001
444 M. El-Hariri et al.300–400 mm. number of signals averaged: 2.matrix: 192 · 256.
voxel size: 2.05 and 2.45 and tridirectional diffusion gradients
at b values of (0 500 s/mm2).
2.1.4. ADC quantiﬁcation
It was performed by using dedicated standard software on a
workstation to obtain ADC maps for b value = 500. Circular
regions of interest (ROIs; measuring 10–20 mm2) were applied
to measure mean signal intensity (SI) in the liver and the spleen
on ADC map avoiding areas of artifact, vessels, and focal le-
sions. The ﬁnal ADC of the liver is the average of the four
ROIs applied to lateral and medial segments of the left lobe,
and the anterior and posterior segments of the right lobe).
Normalized liver ADC was calculated as the ratio of liver
ADC to spleen ADC.
2.2. Histopathologic evaluation
All case group patients (thirty-four) underwent percutaneous
liver biopsy, which was done after the MRI study (mean delay,
35 days; range, 12–54 days) by an experienced hepatologist
using 18–20 gauge needle under sonographic guidance and
was classiﬁed according to the criteria of the METAVIR scor-
ing systems. The METAVIR score is comprised of ﬁve pro-
gressive stages: F0, normal; F1, portal ﬁbrosis; F2, few
ﬁbrotic septae; F3, numerous septae; and F4, cirrhosis (27).
2.3. Data analysis
The analysis of data was done using commercially available
PC-based software package (SPSS) to test statistically signiﬁ-
cant difference. The sensitivity, speciﬁcity and accuracy of liver
ADC and normalized liver ADC were calculated. Student’s t-
test was used to compare between two groups, while One Way
Anova test was used to compare between more than two
groups and Post Hoc analysis (LSD). Pearson’s correlation be-
tween the liver ADC and normalized liver ADC values and his-
tologic grade were done. MCnemar test was used to calculate
concordance between the liver and normalized liver ADC
values.
Receiver operating characteristic (ROC) curve analysis was
used to determine the area under the ROC curve (AUC), and
the threshold liver ADC or normalized liver ADC used to
maximize the average of sensitivity and speciﬁcity and to pro-
vide the highest overall accuracy in differentiation of hepatic
ﬁbrosis from normal one as well as to distinguish between dif-
ferent stages of ﬁbrosis
The P-value was considered signiﬁcant if 60.05 at conﬁ-
dence interval 95%.
3. Results
3.1. Histopathologic Results
The distribution of ﬁbrosis stage (F) in this study was: stage 0
(n = 15, all control subjects were considered to have no ﬁbro-
sis), stage 1 (n = 6), stage 2 (n = 6), stage 3 (n = 9), and stage
4 (cirrhosis, n = 13).
The mean Spleen ADC was lower than liver ADC for all
subjects, while there was no signiﬁcant difference between
spleen ADC values among patients in comparison to control(1.107 ± 0.07 vs. 1.12 ± 0.068, p= 0.998), also there was no
signiﬁcant difference in the spleen ADC between different
stages of ﬁbrosis (p= 0.59–0.89).(Table 1).
The mean liver ADC value of the liver in the control group
was 1.67 · 103 mm2/s and in patients with hepatic ﬁbrosis
was 1.59 · 103 mm2/s. The mean ADC value was signiﬁcantly
lower in patients with hepatic ﬁbrosis compared to volunteers
(P= 0.01) (Table 1) (Fig. 1).
Liver ADC value decreased with increasing ﬁbrosis stage
but there were some overlaps in different grades. Liver ADC
could not signiﬁcantly differentiate different individual stages
of ﬁbrosis except between stages 0 and 4. Liver ADC had sig-
niﬁcant differences between stages 0–1 vs. stage 2–4, stage 0–2
vs. stage 3–4 as well as stage 0–3 vs. stage 4 (Table 2).
Signiﬁcant negative correlation was detected between liver
ADC value and grade of ﬁbrosis (r= 0.361, p= 0.05)
The mean normalized liver ADC value of the liver in volun-
teers was 1.51 · 103 mm2/s and in patients with hepatic ﬁbro-
sis, it was 1.46 · 103 mm2/s. The mean normalized liver ADC
value was signiﬁcantly lower in patients with hepatic ﬁbrosis
compared to volunteers (P< 0.001) (Table 1) (Figs. 2 and 3).
Normalized liver ADC value decreased with increasing
ﬁbrosis stage but there were some overlaps in different grades.
Normalized liver ADC was signiﬁcantly different between
stage 0 and stage 2, 3, and 4 as well as between stage 1 and
stage 4. In addition, it had a trend toward signiﬁcance between
stage 0 and 1, stage 2 and 4 as well as stage 3 and 4. While no
signiﬁcant difference was detected between stages 1 and 2,
stage 1 and 3, stages 2 and 3 (Table 2) (Figs. 4 and 5).
Normalized liver highly signiﬁcant differences between
stages 0–1 vs. stage 2–4, stage 0–2 vs. stage 3–4 as well as stage
0–3 vs. stage 4.
Signiﬁcant negative correlation was detected between nor-
malized liver ADC value and grade of ﬁbrosis (r= 0.694,
p= 0.01).
ROC analysis showed higher performance using normal-
ized liver ADC in comparison to liver ADC, with higher
AUC, sensitivity, and speciﬁcity for detection of ﬁbrotic stages
P2 (0.88, 92.5% and 76.2% vs. 0.72, 82.1%, and 57.1%
respectively). The corresponding values for stages P3 was
0.83, 100%, and 55% vs. 0.69, 77.3%, and 44.4% respec-
tively), while the corresponding values for cirrhosis (stage 4)
Fig. 2 DWI at b= 0 (a), b= 500(b), and ADC map(c) for a patient with stage 1: liver ADC= 1.63 · 103 mm2/s and normalized liver
ADC= 1.48.
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69.2%, 72.2%.for ADC liver (Table 3) (Fig. 6).
4. Discussion
Recent technical improvements in MRI have made clinical
applications of diffusion-weighted imaging (DWI) in the
abdomen feasible. Many researchers have tried to evaluate
the impact of apparent diffusion coefﬁcient (ADC) measure-
ments in the assessment of liver diseases (16,28,29). A growingbody of literature had demonstrated that the ADC of cirrhotic
livers is signiﬁcantly lower than that of normal livers
(3,10,13,17–21,30). In current study, we conﬁrmed this results,
as we found that the mean liver ADC value in patients with
hepatic ﬁbrosis was signiﬁcantly lower than that of volunteers
(1.59 · 103 mm2/s vs. 1.67 · 103 mm2/s, p= 0.01). This can
be attributed to the presence of ﬁbrous tissue. The main
component of ﬁbrous tissue is collagen that associated with
restricted diffusion and subsequent diminished ADC values
(9,31).
Fig. 3 DWI at b= 0 (a), b= 500(b), and ADC map(c) for a patient with stage 2 liver ADC= 1.58 · 103 mm2/s and normalized liver
ADC= 1.46.
446 M. El-Hariri et al.Several reports (11,13,17,19,21,22) reported a negative cor-
relation between the mean ADC value and ﬁbrosis score. This
is consistent with our study as we also demonstrated a signif-
icant negative correlation between liver ADC value and grade
of ﬁbrosis (r= 0.361, p= 0.05).
In contrast, Boulanger et al. (18), reported no correlation
between the ADC values and ﬁbrosis scores measured using
the Ishak scale with ﬁve different b values, ranging between
50 and 250 s/mm2.However, absolute ADC values obtained with DWI are
limited by reproducibility and noise contamination (32,33),
The variability in reported ADC values is further complicated
by the use of different b values and acquisition methods based
on breath-hold, free-breathing, or respiratory triggered tech-
niques, which can affect ADC quantiﬁcation (23,34,35). For
example, in our study mean liver ADC (b= 500) for control
group was 1.67 ± 0.16 · 103 mm2/s., while in a previous
study (10), the mean liver ADCs for stage 0 was
Fig. 4 DWI at b= 0 (a), b= 500(b), and ADC map(c) for a patient with stage 3 liver ADC= 1.59 · 103 mm2/s and normalized liver
ADC= 1.45.
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values of 0 and 500 s/mm2, respectively. Also, Girometti et al.
(14) reported liver ADCs of 1.14 · 103 mm2/s in cirrhotic li-
ver when using b values of 0, 150, 250, and 400 s/mm2 and
ADCs of 0.91 · 103 mm2/s when using b values of 600 and
800 s/mm2.
So, normalization of ADC using a reference organ which
remains relatively constant among patients may aid in reduc-
tion of ADC calculation variability (10). The spleen has been
proven to be a most reliable internal standard wherever quan-titative analysis using ratios is required as in assessing degree
of signal intensity loss in adrenal masses in MRI.(28,36).
In the study carried out by Kim et al. (21), the spleen ADCs
did not differ between patients with chronic liver disease and
healthy liver volunteers. This is supported by our study as
there was no signiﬁcant difference between spleen ADC values
among patients in comparison to control (1.1073 ± 0.0719 ·
103mm2/s vs. 1.1206 ± 0.0689 · 103mm2/s, p= 0.998), also
there was no signiﬁcant difference in the spleen ADC between
different stages of ﬁbrosis (p= 0.59–0.89).
Fig. 5 DWI at b= 0 (a), b= 500(b), and ADC map(c) for a patient with stage 4 liver ADC= 1.55 · 103 mm2/s and normalized liver
ADC= 1.42.
448 M. El-Hariri et al.In a study carried out by Yu et al. (37) aimed to discuss the
diagnostic accuracy of normalized liver ADC using the spleen
and renal cortex as reference organs for the diagnosis of liver
ﬁbrosis. They found that spleen normalized liver ADC (S-
ADC) improves diagnostic accuracy for detection of liver
ﬁbrosis more than liver ADC and renal normalized liver
ADC (R-ADC). S-ADC was superior to liver ADC and R-
ADC for detection of stage 2, 3 and 4 of ﬁbrosis. They also
demonstrated that the correlation between ﬁbrosis stage and
S-ADC was stronger than between ﬁbrosis stage and liverADC and R-ADC (r= 0.71, 0.51, 0.41 respectively;
P< 0.01). In the current study, both liver ADC and normal-
ized liver ADC had signiﬁcant negative correlation with the
grade of ﬁbrosis, however it was more powerful for normalized
liver ADC in comparison to liver ADC (r= 0.694 vs.
0.361, p= 0.01 vs. 0.05).
In the current study, liver ADCs could not signiﬁcantly dif-
ferentiate different individual stages of ﬁbrosis except between
stages 0 and 4. Liver ADC had signiﬁcant differences between
stages 0–1 vs. stage 2–4, stage 0–2 vs. stage 3–4 as well as stage
Table 3 ROC Analysis for performance of Liver ADC versus normalized liver ADC.
Fibrosis Stage Liver ADC Normalized liver ADC P
Cutoﬀ (· 103 mm2/s) AUC Sensitivity (%) Speciﬁcity (%) Cutoﬀ (· 103 mm2/s) AUC Sensitivity (%) Speciﬁcity (%)
FP 2 1.65 0.72 82.1 57.1 1.49 0.88 92.5 76.2 0.42
FP 3 1.65 0.69 77.3 44.4 1.48 0.83 100.0 55.0 0.03
FP 4 1.57 0.74 69.2 72.2 1.46 0.87 81.8 81.8 0.80
Fig. 6 Receiver operating characteristic curves for liver apparent diffusion coefﬁcient (liver ADC) and normalized liver ADC in
distinguishing subset of patients stratiﬁed by ﬁbrosis stage, detection of stage P2 (a); detection of stage P3 (b); detection of cirrhosis
[stage P4] (c). (Refer Table 3 for area under the curve values).
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different between stage 0 and stages 2, 3, and 4 as well as be-
tween stage 1 and stage 4. In addition, it had a trend toward
signiﬁcance between stage 0 and 1, stages 2 and 4 as well as
stages 3 and 4. While no signiﬁcant difference was detected be-
tween stages 1 and 2, stages 1 and 3 and stages 2 and 3. Nor-
malized liver highly signiﬁcant differences between stages 0–1
vs. stage 2–4, stage 0–2 vs. stage 3–4 as well as stage 0–3 vs.
stage 4.
Our results are close to earlier study (10) which concluded
that liver ADC failed to distinguish individual stages of ﬁbro-
sis, except between stages 0 and 4. While the normalized liver
ADC had signiﬁcant difference between control livers and
intermediate stages of ﬁbrosis (stages 2–3) and cirrhosis (stage
4) as well as between stages 1 and 4, while a trend toward sig-
niﬁcance was achieved between stages 0 and 1 (p= 0.051) and
stages 1 and 3 (p= 0.06).Previous studies had reported AUC values of 0.655–0.790
for the detection of liver ﬁbrosis stage P2, 0.689–0.92 for
the detection of ﬁbrosis stage P3 and 0.720–0.93 for the
detection of cirrhosis using liver ADC (10,12–14). In an ear-
lier report (10) ROC analysis showed that normalized liver
ADC was superior to liver ADC for detection of stage
P2 (area under the ROC curve, 0.864 vs. 0.655;
p = 0.013) and stage P3 (0.805 vs. 0.689; p = 0.015), with-
out a signiﬁcant difference for diagnosing cirrhosis (0.935 vs.
0.720; p = 0.185).
This agrees with the current study, as ROC analysis showed
higher performance using normalized liver ADC in compari-
son to liver ADC, with higher AUC, sensitivity, and speciﬁcity
for detection of ﬁbrotic stagesP2 (0.88, 92.5% and 76.2% vs.
0.72, 82.1%, and 57.1% respectively). The corresponding val-
ues for stages P3 was 0.83, 100%, and 55% vs. 0.69, 77.3%,
and 44.4% respectively), while the corresponding values for
450 M. El-Hariri et al.cirrhosis (stage 4) was 0.87, 81.8% and 81.8% for normalized
liver ADC versus 0.74, 69.2%, 72.2%.for ADC liver.
In addition, this supports the previous report (38) which
encouraged the value of using the spleen as a reference organ
to improve the performance of ADC measurement for the
diagnosis of cirrhosis. In that report authors demonstrated a
cutoff <1.4 to have sensitivity of 78% and speciﬁcity of
80% for diagnosing cirrhosis and they suggested that the nor-
malized liver ADC may potentially serve as a tool for the
detection of early cirrhosis in a morphologically normal
appearing liver on conventional MR imaging.
We acknowledge some limitations of our study. The time
interval between histopathological examination and MRI var-
ied with a mean interval of 35 days and a maximum interval of
54 days. Despite this relatively small time interval, ﬁbrosis pro-
gression or medical therapy may alter the degree of ﬁbrosis.
The relatively small number of subjects especially patients at
early stage of liver ﬁbrosis was another limitation factor.
In conclusion, our results demonstrated the utility of using
the spleen as a reference organ to improve the diagnostic per-
formance of ADC measurement for the diagnosis of liver
ﬁbrosis. The application of this promising technique for the
evaluation of liver ﬁbrosis may help to obviate the need for
a liver biopsy for ﬁbrosis staging in some patients.
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